000176881 001__ 176881
000176881 005__ 20240229133722.0
000176881 0247_ $$2doi$$a10.1007/s00392-021-01939-3
000176881 0247_ $$2pmid$$apmid:34546427
000176881 0247_ $$2pmc$$apmc:PMC8453472
000176881 0247_ $$2ISSN$$a0300-5860
000176881 0247_ $$2ISSN$$a1435-1285
000176881 0247_ $$2ISSN$$a1861-0684
000176881 0247_ $$2ISSN$$a1861-0692
000176881 0247_ $$2altmetric$$aaltmetric:113885271
000176881 037__ $$aDKFZ-2021-02123
000176881 041__ $$aEnglish
000176881 082__ $$a610
000176881 1001_ $$aRieder, Marina$$b0
000176881 245__ $$aPre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities.
000176881 260__ $$aBerlin$$bSpringer$$c2022
000176881 3367_ $$2DRIVER$$aarticle
000176881 3367_ $$2DataCite$$aOutput Types/Journal article
000176881 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1646136132_20513
000176881 3367_ $$2BibTeX$$aARTICLE
000176881 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000176881 3367_ $$00$$2EndNote$$aJournal Article
000176881 500__ $$a111, pages 322–332 (2022)
000176881 520__ $$aCoagulopathy and venous thromboembolism are common findings in coronavirus disease 2019 (COVID-19) and are associated with poor outcome. Timely initiation of anticoagulation after hospital admission was shown to be beneficial. In this study we aim to examine the association of pre-existing oral anticoagulation (OAC) with outcome among a cohort of SARS-CoV-2 infected patients.We analysed the data from the large multi-national Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) from March to August 2020. Patients with SARS-CoV-2 infection were eligible for inclusion. We retrospectively analysed the association of pre-existing OAC with all-cause mortality. Secondary outcome measures included COVID-19-related mortality, recovery and composite endpoints combining death and/or thrombotic event and death and/or bleeding event. We restricted bleeding events to intracerebral bleeding in this analysis to ensure clinical relevance and to limit reporting errors. A total of 1 433 SARS-CoV-2 infected patients were analysed, while 334 patients (23.3%) had an existing premedication with OAC and 1 099 patients (79.7%) had no OAC. After risk adjustment for comorbidities, pre-existing OAC showed a protective influence on the endpoint death (OR 0.62, P = 0.013) as well as the secondary endpoints COVID-19-related death (OR 0.64, P = 0.023) and non-recovery (OR 0.66, P = 0.014). The combined endpoint death or thrombotic event tended to be less frequent in patients on OAC (OR 0.71, P = 0.056).Pre-existing OAC is protective in COVID-19, irrespective of anticoagulation regime during hospital stay and independent of the stage and course of disease.
000176881 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000176881 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000176881 650_7 $$2Other$$aCOVID-19
000176881 650_7 $$2Other$$aOral anticoagulation
000176881 650_7 $$2Other$$aSARS-CoV-2
000176881 650_7 $$2Other$$aThrombosis
000176881 7001_ $$00000-0002-1276-9920$$aGauchel, Nadine$$b1
000176881 7001_ $$aKaier, Klaus$$b2
000176881 7001_ $$aJakob, Carolin$$b3
000176881 7001_ $$aBorgmann, Stefan$$b4
000176881 7001_ $$aClassen, Annika Y$$b5
000176881 7001_ $$aSchneider, Jochen$$b6
000176881 7001_ $$aEberwein, Lukas$$b7
000176881 7001_ $$0P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439$$aLablans, Martin$$b8$$udkfz
000176881 7001_ $$aRüthrich, Maria$$b9
000176881 7001_ $$aDolff, Sebastian$$b10
000176881 7001_ $$aWille, Kai$$b11
000176881 7001_ $$aHaselberger, Martina$$b12
000176881 7001_ $$aHeuzeroth, Hanno$$b13
000176881 7001_ $$aBode, Christoph$$b14
000176881 7001_ $$avon Zur Mühlen, Constantin$$b15
000176881 7001_ $$aRieg, Siegbert$$b16
000176881 7001_ $$aDuerschmied, Daniel$$b17
000176881 773__ $$0PERI:(DE-600)2218331-0$$a10.1007/s00392-021-01939-3$$p322–332$$tClinical research in cardiology$$v111$$x1861-0692$$y2022
000176881 909CO $$ooai:inrepo02.dkfz.de:176881$$pVDB
000176881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000176881 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000176881 9141_ $$y2021
000176881 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000176881 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000176881 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000176881 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000176881 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN RES CARDIOL : 2021$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-08
000176881 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN RES CARDIOL : 2021$$d2022-11-08
000176881 9201_ $$0I:(DE-He78)E260-20160331$$kE260$$lVerbundinformationssysteme$$x0
000176881 980__ $$ajournal
000176881 980__ $$aVDB
000176881 980__ $$aI:(DE-He78)E260-20160331
000176881 980__ $$aUNRESTRICTED